Should we target signal pathways instead of single mediators in the treatment of sepsis?

Contributions to Nephrology

Volumn 132, Issue , 2001, Pages 400-414

  Wratten, Mary Lou ^a   Brendolan, Alessandra ^b   Ronco, Claudio ^b   La Greca, Giuseppe ^b   Tetta, Ciro ^a  

^a Cyberonics Inc   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CARRIER PROTEIN; COMPLEMENT COMPONENT C5A; FREE RADICAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; LIPOSOME; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

DRUG ANTAGONISM; HEMOFILTRATION; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SEPSIS;

ACUTE-PHASE PROTEINS; CARRIER PROTEINS; COMPLEMENT C5A; FREE RADICALS; HEMOFILTRATION; HUMANS; LIPOSOMES; MEMBRANE GLYCOPROTEINS; NF-KAPPA B; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035532697     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000060109     Document Type: Article

References (104)

1. Wheeler A, Bernard G: Treating patients with severe sepsis. N Engl J Med 1999;340:207-214.
2. Rangel-Frausto, MS, Pittet D, Costigan M, Hwang T, Davis C, Wenzel R: The natural history of the systemic inflammatory response syndrome: A prospective study. JAMA 1995;273:117-123.
3. Oberholzer A, Oberholzer C, Moldawer L: Cytokine signaling - Regulation of the immune response in normal and critically ill states. Crit Care Med 2000;28:N3-N12.
4. Bone R: Sir Isaac Newton, sepsis, SIRS and CARS. Crit Care Med 1996;24:1125-1128.
5. Dinarello C: Proinflammatory cytokines. Chest 2000;118:503-508.
6. Pruitt J, Welborn M, Edwards P, Harward T, Seeger J, Martin T, Mith C, Kenney J, Wesdorp R, Mijer S, Cuesta M, Abouhanze A, Copeland E, Giri J, Sims J, Moldawer L, Oldenburg H: Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome. Blood 1996;87:3282-3288.
7. Natanson C, Esposito C, Banks S: The sirens' songs of confirmatory sepsis trials: Selection bias and sampling error. Crit Care Med 1998;26:1927-1931.
8. Nasraway S: Sepsis research: We must change course. Crit Care Med 1999;27:427-430.
9. Bernard G: Research in sepsis and acute respiratory syndrome: Are we changing course? Crit Care Med 1999;27:434-436.
10. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light R, Poole L, Allred R, Constant J, Pennington J, Porter S: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998;351:929-933.
11. Cohen J, Carlet J: INTERSEPT: An international multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996;24:1431-1440.
12. Abraham E, Glauser M, Butler T, Garbino J, Gelmont D, Laterre P, Kudsk K, Bruining H, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A: P55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. Ro 45-2081 Study Group. JAMA 1997;277:1531-1538.
13. Fisher C, Dhainaut J, Opal S, Pribble J, Balk R, Slotman G, Iberti T, Rackow E, Shapiro M, Greenman R: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271:1836-1843.
14. Opal S, Fisher C, Khainaut F: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III randomized double-blind, placebo-controlled multicenter trial. Crit Care Med 1997;25: 1115-1124.
15. Fein A, Bernard G, Criner G, Bernard G, Criner G, Fletcher E, Good J, Knaus W, Levy H, Matuschak G, Hanies H, Taylor R, Rodell T: Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127): Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 1997; 277.
16. Bernard G, Wheeler A, Russell J, et al: The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997;336:912-918.
17. Dhainaut J, Tenaillon A, Le Tulzo Y, et al: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 1994;22:1720-1728.
18. Dhainaut J, Tenaillon A, Hemmer M, et al: Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: A phase III, randomized, doubleblind, placebo-controlled multicenter trial. Crit Care Med 1998;26:1963-1971.
19. Grootendorst A, Von Bommel E, Van Leengoed L, van Zanten A, Huipen H, Goenveld A: Infusion of ultrafiltrate from endotoxemic pigs depresses myocardial performance in normal pigs. J Crit Care 1993;8:161-169.
20. Tracey K, Fong Y, Hesse K, Monogue A, Kuo G, Lowry S, Cerami A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987;330:662-664.
21. Ashkenazi A, Marsters S, Capon D, Chamow S, Figari I, Pennica D, Goeddel D, Palladino M, Smith D: Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 1991;88:10535-10539.
22. Pfeffer K, Matsuyama T, Kundig A, Wakeham K, Kishihara A, Shahinian A, Wiegmann K, Ohashi P, Kronke M, Mak T: Mice deficient for the 55-kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-467.
23. Bohrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Mannel D, Bottiger B, Stern D, Waldherr R, Saeger H, Ziegler R, Bierhaus A, Martin E: Role of NFkB in the mortality of sepsis. J Clin Invest 1997;100:972-985.
24. Guo R, Huber-Lang M, Wang X, Sarma V, Padgaonkar V, Craig R, Riedemann N, McClintock S, Hlang T, Shi M, Ward P: Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest 2000;106:1271-1280.
25. Kirschfink M: Controlling the complement system in inflammation. Immunopharmacology 1997; 38:51-62.
26. Smedegard G, Cui L, Hugli T: Endotoxin-induced shock in the rat. A role for C5a. Am J Pathol 1989;135:489-497.
27. Stevens J: Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986;77:1812-1816.
28. Czermak B, Sarma V, Pierson C, Warner R, Huber-Lang M, Bless N, Schmal H, Fiedl H, Ward P: Protective effects of C5a blockade in sepsis. Nat Med 1999;5:788-792.
29. Bengtsom A, Heideman M: Anaphylatoxin formation in sepsis. Arch Surg 1988;123:645-649.
30. Bernhagen J, Calandra T, Mitchell R, Martin S, Tracey K, Voelter W, Manogue D, Cerami A, Bucala R: MIF is a pituitary-derived cytokine that potentiates lethal endotoximeia. Nature 1993; 365:756-759.
31. Calandra T, Spiegel L, Metz C, Bucala R: Macrophage inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of gram-positive bacteria. Proc Natl Acad Sci USA 1998; 95:11383-11388.
32. Bacher M, Metz C, Calandra T, Mayer K, Chesney J, Lohoff M, Gemsa D, Donnelly T, Bucala R: An essential role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996;93:7849-7854.
33. Calandra T, Bernhagen J, Metz C, Spiegel L, Bacher M, Donnelly T, Cerami A,Bucala R: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377:68-71.
34. Calandra T, Echtenacher B, Le Roy D, Pugin J, Metz C, Hultner L, Heumann D, Mannel D, Bucala R, Glauser M: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000;6:164-170.
35. Homma N, Koseki H, Akasaka T, Nakayama T, Taniguchi M, Serizawa I, Akahori H, Osawa M, Mikayama T: Deficiency of the macrophage migration inhibitory factor gene has no significant effect on endotoxemia. Immunology 2000;100:84-90.
36. Gallay P, Barras C, Tobias P, Calandra T, Glause M, Heumann D: Lipopolysaccharide (LPS) binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS. J Infect Dis 1994;170:1319-1322.
37. Froon A, Dentener M, Greve J, Ramsay G, Buurman W: Lipopolysaccharide toxicity-regulating proteins in bacteremia. J Infect Dis 1995;170:1250-1257.
38. Lamping N, Dettmer R, Schroder N, Pfeil D, Hallatschek W, Burger R, Schumann R: LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 1998;101:2065-2071.
39. Goldfarb R: Investigations into the polydeterminant nature of sepsis. Crit Care Med 1999;27:2587-2588.
40. Abraham E: NFκB activation. Crit Care Med 2000;28:N100-N104.
41. Baldwin A: The NFκB and IκB proteins: New discoveries and insights. Annu Rev Immunol 1996; 14:649-681.
42. Schwartz M, Moore E, Moore F, Shenkar R, Moine P, Haenel J, Abraham E: NFκB is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med 1996; 24:1285-1292.
43. Schreck R, Ireber P, Baeuerle P: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NFκB transcription factor and HIV-1. EMBO J 1991;10:2247-2258.
44. 2 and antioxidants have opposite effects on activation of NFκB and AP-1 in intact cells: AP-1 as secondary antioxidant response factor. EMBO J 1993;12: 2005-2015.
45. Janssen-Henninger Y, Macara I, Mossman B: Cooperativity between oxidants and tumor necrosis factor in the activation of nuclear factor (NF)-κB. Requirements of Ras/mitogen-activated protein kinases in the activation of NFκB by oxidants. Am J Respir Cell Mol Biol 1999;20:942-952.
46. Thannickal V, Fanburg B: Reactive oxygen species in cell signaling. Am J Physiol 2000;279:L1005-L1028.
47. Kazzaz J, Xu J, Palaia T, Mantell L, Fein A, Horowitz S: Cellular oxygen toxicity. J Biol Chem 1996;271:15182-15186.
48. Dalton T, Shertzer H, Puga A: Regulation of gene expression by reactive oxygen. Annu Rev Pharmacol Toxicol 1999;39:67-101.
49. Basu S, Eriksson M: Oxidative injury and survival during endotoxemia. FEBS Lett 1998;438:159-160.
50. Cowley H, Bacon P, Goode H, Webster N, Jones J, Menon D: Plasma antioxidant potential in severe sepsis: A comparison of survivors and nonsurvivors. Crit Care Med 1996;24:1179-1183.
51. Flowers F, Zimmermann J: Reactive oxygen species in the cellular pathophysiology of shock. New Horiz 1998;6:169-180.
52. Galley H, Howdle P, Walker B, Webster N: The effects of intravenous antioxidants in patients with septic shock. Free Radic Biol Med 1997;23:768-774.
53. Novelli G: Role of free radicals in septic shock. J Physiol Pharmacol 1998;48:512-527.
54. Schorah C, Downing C, Piripitsi A, Gallivan L, Al-Hazaa A, Sanderson M, Bodenham A: Total vitamin C, ascorbic acid and dehydroascorbic acid concentrations in plasma of critically ill patients. Am J Clin Nutr 1996;63:760-765.
55. Sugino K, Dohi K, Yamada K, Kawasaki T: The role of lipid peroxidation in endotoxin-induced hepatic damage and the protective effect of antioxidants. Surgery 1987;101:746-752.
56. Walker P, Shah S: Reactive oxygen metabolites in endotoxin-induced acute renal failure in rats. Kidney International 1990;38:1125-1132.
57. Tanswell A, Freeman B: Antioxidant therapy in critical care medicine. New Horiz 1995;3:330-341.
58. Blackwell T, Blackwell T, Holden E, Christman B, Christman J: In vivo antioxidant treatment suppresses nuclear factor-κB activation and neutrophilic lung inflammation. J Immunol 1996;157: 1630-1637.
59. Kunimoto F, Morita T, Ogawa R, Fujita T: Inhibition of lipid peroxidation improves survival rate of endotoxemic rats. Circ Shock 1987;21:15-22.
60. Oldham K, Bowen P: Oxidative stress in critical care: Is antioxidant supplementation beneficial? J Am Diet Assoc 1998;98:1001-1008.
61. Powell R, Machiedo G, Rush B, Dikdan G: Effect of oxygen free radical scavengers on survival in sepsis. Am Surg 1991;57:86-88.
62. Suntres Z, Shek P: Treatment of LPS-induced tissue injury: Role of liposomal antioxidants. Shock 1996;6 (suppl 1):S57-S64.
63. Suntres Z, Shek P: Prophylaxis against lipopolysaccharide-induced acute lung injury by α-tocopherol liposomes. Crit Care Med 1998;26:723-729.
64. Rojas C, Cadenas S, Herrero A, Medndez J, Barja G: Endotoxin depletes ascorbate in the guinea pig heart. Protective effects of vitamins C and E against oxidative stress. Life Sci 1996;59:649-657.
65. Zurovsky Y, Zadok I: Antioxidants attenuate glycerol-endotoxin-induced acute renal failure in rats. J Endotox Res 1995;2:365-370
66. Zurovsky Y Gispaan I: Antioxidants attenuate endotoxin-induced acute renal failure in rats. Am J Kidney Dis 1995;25:51-57.
67. Vaughan D, Yanay O, Zimmermann J: Deciphering the oxyradical inflammation Rosetta stone. Crit Care Med 1999;27:1666-1669.
68. Tetta C, Mariano F, Baudes J, Ronco C, Wratten M, Camussi G: Relevance of platelet-activating factor in inflammation and sepsis: Mechanisms and kinetics of removal in extracorporeal treatments. Am J Kidney Dis 1997;30:S57-S65.
69. De Vriese A, Colardyn F, Philippe J, Vanholder R, De Sutter J, Lameire N: Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999;10:846-853.
70. Tetta C, Gianotti L, Cavaillon J, Wratten M, Fini M, Braga M, Bisagni P, Giavaresi G, Bolzani R, Giardino R: Coupled plasma filtration-adsorption in a rabbit model of endotoxic shock. Crit Care Med 2000;28:1526-1533.
71. Ronco C, Brendolan A, Dan M, Piccinni P, Bellomo R, De Nitti C, Inguaggiato P, Tetta C: Adsorption in sepsis. Kidney Int 2000;76:S148-155.
72. Stange J, Mitzner S, Risler T, Erley C, Lauchart W, Goehl H, Lammt S, Peszynski P, Freytag J, Hickstein H, Lohr M, Liebe S, Schareck W, Hopt U, Schmidt R: Molecular adsorbent recycling system: Clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999;23:319-330.
73. Ash S, Steczko J, Knab W, Blake D, Carr D, Harker K, Levy H: Push-pull sorbent-based pheresis and hemodiabsorption in the treatment of hepatic failure: Preliminary results of a clinical trial with the BioLogic-DTPF system. Ther Apher 2000;4:218-228.
74. Wratten M, Sereni L, Tetta C: Hemolipodialysis attenuates oxidative stress and removes hydrophobic toxins. Artif Organs 2000;24:685-690.
75. Wratten M, Navino C, Tetta C, Verzetti G: Haemolipodialysis. Blood Purif 1999;17:127-133.
76. Adler-Moore J: AmBisome targeting to fungal infections. Bone Marrow Transplant 1994;14(suppl 5):S3-S7.
77. Allen TM: Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994;15:215-220.
78. Alving CR, Verma JN, Rao M, Krzych U, Amselem S, Green SM, Wassef NM: Liposomes containing lipid A as a potent non-toxic adjuvant. Res Immunol 1992;143:197-198.
79. Bakker-Woudenberg IA, Lokerse AF, ten Kate MT, Mouton JW, Woodle MC, Storm G: Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. J Infect Dis 1993;168:164-171.
80. Bermudez LE: Use of liposome preparation to treat mycobacterial infections. Immunobiology 1994;191:578-583.
81. Beach MC, Morley J, Spiryda L, Weinstock SB: Effects of liposome encapsulated hemoglobin on the reticuloendothelial system. Biomater Artif Cells Immobilization Biotechnol 1992;20:771-776.
82. de Marie S, Janknegt R, Bakker-Woudenberg IA: Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994;33:907-916.
83. Farhood H, Gao X, Son K, Yang YY, Lazo JS, Huang L, Barsoum J, Bottega R,Epand RM: Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann N Y Acad Sci 1994;716:23-34.
84. Gregoriadis G, Florence AT: Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 1993;45:15-28.
85. Sampedro F, Partika J, Santalo P, Molins-Pujol AM, Bonal J, Perez-Soler R: Liposomes as carriers of different new lipophilic antitumour drugs: A preliminary report. J Microencapsul 1994;11:309-318.
86. Shek PN, Suntres ZE, Brooks JI: Liposomes in pulmonary applications: Physicochemical considerations, pulmonary distribution and antioxidant delivery. J Drug Target 1994;2:431-442.
87. Timofeev BA, Bolotin IM, Stepanova LP, Bogdanov AA Jr, Georgiu K, Malyshev SN, Petrovsky VV, Klibanov AL, Torchilin VP: Liposomal diamidine (imidocarb): Preparation and animal studies. J Microencapsul 1994;11:627-632.
88. Tollbom O, Chojnacki T, Dallner G: Transfer of liposomes containing dolichol into isolated hepatocytes. Lipids 1992;27:248-54.
89. Touitou E, Junginger HE, Weiner ND, Nagai T, Mezei M: Liposomes as carriers for topical and transdermal delivery. J Pharm Sci 1994;83:1189-1203.
90. Wassef NM, Alving CR, Richards RL: Liposomes as carriers for vaccines. Immunomethods 1994;4: 217-222.
91. Halliwell B: Vitamin C: Antioxidant or pro-oxidant in vivo. Free Radic Res 1996;25:439-454.
92. Zucker S, Goessling W, Hoppin A: Unconjugated bilirubin exhibits spontaneous diffusion through model lipid bilayers and native hepatocyte membranes. J Biol Chem 1999;274:10852-10862.
93. Zucker SD, Goessling W, Gollan JL: Kinetics of bilirubin transfer between serum albumin and membrane vesicles. J Biol Chem 1995;270:1074-1081.
94. Zucker SD, Goessling W, Zeidel ML, Gollan JL: Membrane lipid composition and vesicle size modulate bilirubin intermembrane transfer. Evidence for membrane-directed trafficking of bilirubin in the hepatocyte. J Biol Chem 1994;269:19262-1970.
95. Zucker S, Storch J, Zeidel M, Gollan J: Mechanism of the spontaenous transfer of unconjugated bilirubin between small unilamellar phosphatidylcholine vesicles. Biochemistry 1992;31:3184-3192.
96. Whitmer D, Ziurys J, Gollan J: Hepatic microsomal glucuronidation of bilirubin in unilamellar liposomal membranes. Implications for intracellular transport of lipophilic substrates. J Biol Chem 1984;259:11969-11975.
97. Tipping E, Ketterer B, Christodoulides L: Interactions of small molecules with phospholipid bilayers. Binding to egg phosphatidylcholine of some organic anions (bromosulphophthalein, oestrone sulphate, haem and bilirubin) that bind to ligandin and aminoazo-dye binding protein A. Biochem J 1979;180:327-337.
98. Tazuma S, Holzbach R: Transport of conjugated bilirubin and other organic anions in bile: Relation to biliary lipid structures. Proc Natl Acad Sci USA 1987;84:2052-2056.
99. Noy N, Leonard M, Zakim D: The kinetics of interactions of bilirubin with lipid bilayers and with serum albumin. Biophys Chem 1992;42:177-188.
100. Hayward D, Schiff D, Fedunec S, Chan G, Davis P, Poznansky M: Bilirubin diffusion through lipid membranes. Biochim Biophys Acta 1986;860:149-153.
101. Eriksen E, Danielsen H, Brodersen R: Bilirubin-liposome interaction. Binding of bilirubin dianion, protonization and aggregation of bilirubin acid. J Biol Chem 1981;256:4269-4274.
102. Cestaro B, Crvato G, Ferrari S, Di Silvestro G, Monti D, Manitto P: Interaction of bilirubin with small unilamellar vesicles of dipalmitoylphosphatidylcholine. Ital J Biochem 1983;32:318-329.
103. Harmon P, Cabral-Lilly D, Reed R, Maurio F, Franklin J, Janoff A: The release and detection of endotoxin from liposomes. Anal Biochem 1997;250:139-146.
104. Wurfel M, Wright S: Lipopolysaccharide binding and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers: Preferential interaction with particular classes of lipids. J Immunol 1997; 158:3925-3934.